The article studies the effect of subcutaneous sumatriptan in trigeminal neuralgia. Refractory patients were randomized to receive either placebo or sumatriptan and crossed over after one week for a second treatment. Paroxysmal pain, which was triggered by touching or moving the face, was measured with VAS before and fifteen minutes after study treatment.